PSA on TRT: What Testosterone Replacement Therapy Does to Prostate-Specific Antigen

How TRT Affects PSA Levels

Prostate-specific antigen is a serine protease produced by prostatic epithelial cells. Testosterone activates the androgen receptor in those cells, which upregulates PSA gene transcription. When exogenous testosterone restores serum levels from hypogonadal to mid-normal range, PSA production increases proportionally.

The Magnitude of the Rise

A 2016 meta-analysis of 22 randomized controlled trials (N=2,351) found that TRT raised PSA by a weighted mean of 0.10 ng/mL at 3 months and 0.47 ng/mL at 12 months compared to placebo [1]. The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies enrolling 790 men aged 65 and older with testosterone below 275 ng/dL, confirmed that testosterone gel raised PSA by 0.55 ng/mL at 12 months versus a 0.02 ng/dL rise in the placebo arm [2].

Why It Plateaus

The prostate has a finite number of androgen receptors. Once those receptors are saturated (generally around a serum testosterone of 230 to 250 ng/dL, per the saturation model proposed by Morgentaler and Traish), additional testosterone does not drive further PSA elevation [3]. This explains why men whose baseline T sits above the saturation threshold see minimal PSA change on therapy.

When the Rise Is Abnormal

The American Urological Association (AUA) recommends urological evaluation if PSA rises by more than 1.4 ng/mL within any 12-month window or if the absolute value crosses 4.0 ng/mL [4]. A confirmed PSA above that threshold on TRT should prompt a shared decision about MRI-guided biopsy, not automatic discontinuation of therapy.

Baseline Lab Panel Before Starting TRT

No clinician should prescribe testosterone without a comprehensive baseline panel. The reason is simple: you cannot interpret future changes without a reference point.

PSA and Digital Rectal Exam

The Endocrine Society's 2018 clinical practice guideline specifies that PSA and a digital rectal exam (DRE) are required before initiating TRT in men over 40 [5]. Men with a baseline PSA above 4.0 ng/mL (or above 3.0 ng/mL in high-risk populations) should complete urological workup before beginning therapy.

Testosterone: Total and Free

Total testosterone captures all circulating forms: free, albumin-bound, and SHBG-bound. The standard reference range for adult men is roughly 264 to 916 ng/dL using LC-MS/MS (liquid chromatography-tandem mass spectrometry), which the Endocrine Society considers the gold standard assay [5].

Free testosterone represents the 2 to 3% fraction that is unbound and biologically active. Direct analog immunoassays for free T are unreliable. The preferred methods are equilibrium dialysis or, when that is unavailable, the Vermeulen calculation, which derives free T from total T, SHBG, and albumin concentrations [6]. A calculated free testosterone below 5 ng/dL in a symptomatic man supports a hypogonadism diagnosis even when total T falls within the reference range.

Estradiol: Why the Sensitive Assay Matters

Standard immunoassay estradiol tests were designed for female reproductive ranges (30 to 400 pg/mL). They lack precision below 30 pg/mL, exactly the range where male values sit. The estradiol sensitive assay (LC-MS/MS) is accurate to single-digit pg/mL and should be ordered as "estradiol, sensitive" or "estradiol by LC-MS/MS" [7]. Target range for men on TRT is typically 20 to 35 pg/mL. Values above 40 to 50 pg/mL correlate with gynecomastia, water retention, and mood disturbance.

CBC: Hematocrit and Hemoglobin

Testosterone stimulates erythropoiesis via erythropoietin upregulation and direct action on hematopoietic stem cells. A 2017 analysis of the TTrials hematology substudy found that testosterone gel increased hemoglobin by a mean of 1.0 g/dL in men with unexplained anemia (hemoglobin <12.7 g/dL at baseline), resolving anemia in 54% of treated men versus 15% on placebo [8]. This is a therapeutic benefit for anemic men. It is a safety signal for men who enter therapy with a hematocrit already above 50%.

PSA Monitoring Schedule on TRT

The Endocrine Society and AUA agree on a stepwise schedule, though the exact intervals differ by a few months. The HealthRX medical team recommends the following consolidated protocol.

First Year Cadence

Draw PSA at baseline, then again at 3 months and 6 months. The 3-month draw catches rapid, unexpected rises (which may indicate pre-existing occult pathology unmasked by testosterone). The 6-month draw confirms the trajectory. A 12-month draw completes the first-year picture.

Ongoing Monitoring

After the first year, annual PSA is sufficient for men whose values have been stable. Men with a baseline PSA between 2.0 and 4.0 ng/mL, a family history of prostate cancer, or African American ancestry should continue semiannual draws indefinitely [4].

What to Do with a Rising PSA

A single elevated value is not diagnostic. Repeat the test 4 to 6 weeks later after controlling for confounders: ejaculation within 48 hours, urinary tract infection, vigorous cycling, or recent prostate manipulation. If the repeat value confirms the rise, refer to urology. Do not stop TRT reflexively. The TRAVERSE trial (N=5,204), the largest randomized safety trial of TRT to date, found no significant increase in high-grade prostate cancer events in men on testosterone versus placebo over a mean follow-up of 33 months [9].

CBC Monitoring: Hematocrit, Hemoglobin, and Red Cell Indices

Polycythemia is the most common dose-limiting adverse effect of TRT. It is also the most preventable.

Thresholds That Matter

The Endocrine Society sets the action threshold at a hematocrit above 54% [5]. At that level, blood viscosity rises enough to increase thromboembolic risk. Some clinicians prefer a more conservative ceiling of 52%, particularly in men with obstructive sleep apnea or a personal history of venous thromboembolism.

Dose Adjustments vs. Phlebotomy

If hematocrit rises above 54%, the first intervention is dose reduction or lengthening the injection interval. Switching from intramuscular to subcutaneous injection or from injectable to topical testosterone can also lower hematocrit, because topical delivery produces more stable serum levels with lower peak-to-trough variation [10]. Therapeutic phlebotomy (removing 1 unit of whole blood) provides immediate reduction and can be repeated every 8 to 12 weeks if needed while the dose is being titrated down.

Iron Deficiency from Repeated Phlebotomy

Men who require more than two phlebotomies per year should have ferritin and iron saturation checked. Chronic phlebotomy can cause iron-deficiency erythropoiesis even while hematocrit remains elevated. A ferritin below 30 ng/mL in this context warrants iron supplementation and a serious reassessment of testosterone dose [11].

Total Testosterone Range: Interpreting Your Results

"Normal" is a statistical construct derived from population reference ranges. It does not automatically equal optimal for a given patient.

Reference Range vs. Therapeutic Target

The Endocrine Society defines the male reference range as 264 to 916 ng/dL based on harmonized data from the Framingham Heart Study, EMAS, and other cohorts using LC-MS/MS [5]. On TRT, the therapeutic target is a trough level (drawn the morning of the next injection for men on weekly or biweekly protocols) of 450 to 700 ng/dL. Trough values consistently above 900 ng/dL indicate overreplacement and increase hematocrit and estradiol risk.

Timing of the Blood Draw

For men on intramuscular testosterone cypionate or enanthate injected weekly, the trough occurs 6 to 7 days post-injection. Blood drawn 24 to 48 hours after injection captures the peak and will overestimate steady-state levels. The AUA and Endocrine Society both recommend trough draws [4][5]. For men on daily topical testosterone, draw blood 2 to 8 hours after application to capture the absorption peak, which represents the clinically relevant level for that delivery method.

Age-Related Decline

Total testosterone decreases by approximately 1 to 2% per year after age 30. The Baltimore Longitudinal Study of Aging documented a prevalence of total T below 325 ng/dL in 12% of men in their 50s, 19% in their 60s, and 28% in their 70s [12]. Free testosterone declines faster because SHBG rises with age, binding a larger fraction of circulating T.

Free Testosterone Calculation: Methods and Clinical Use

Measuring free testosterone directly by equilibrium dialysis is expensive and available only at reference laboratories. Most clinicians rely on calculated free T.

The Vermeulen Equation

The Vermeulen (or Vermeulen-Manni) calculation uses total testosterone, SHBG, and albumin (assumed at 4.3 g/dL if not measured) to estimate free T via mass action equations [6]. It correlates well with equilibrium dialysis (r = 0.9+) and is endorsed by the Endocrine Society as an acceptable alternative.

When Free T Changes the Diagnosis

A man with a total T of 350 ng/dL and an SHBG of 55 nmol/L may have a calculated free T of 4.2 ng/dL, well below the 5 ng/dL threshold, making him functionally hypogonadal despite a total T that looks borderline acceptable. Conditions that raise SHBG include aging, hyperthyroidism, liver disease, and anticonvulsant use. Conditions that suppress SHBG include obesity, type 2 diabetes, and hypothyroidism [5]. Without free T or at minimum SHBG, total T alone can mislead.

Bioavailable Testosterone

Bioavailable testosterone equals free T plus albumin-bound T (since albumin binding is weak and easily dissociable). Some labs report bioavailable T as a percentage. It offers slightly more clinical information than free T alone but is less standardized across laboratories.

Estradiol Sensitive Assay on TRT

Estradiol in men is produced primarily by aromatase conversion of testosterone in adipose tissue, brain, and bone. More testosterone substrate means more estradiol production.

Why Standard Assays Fail in Men

The standard estradiol immunoassay cross-reacts with C-reactive protein and other steroids at low concentrations, producing falsely elevated readings in men. A 2004 validation study showed that immunoassay overestimated male estradiol by 10 to 20% compared to LC-MS/MS [7]. Prescribing an aromatase inhibitor based on an inaccurate immunoassay result exposes the patient to unnecessary bone-density loss.

Clinical Targets and Symptoms

Dr. Abraham Morgentaler, Associate Clinical Professor of Urology at Harvard Medical School, has stated: "Estradiol in men is not the enemy. It is essential for bone health, cardiovascular protection, and libido. The goal is balance, not suppression" [3].

Target estradiol on TRT: 20 to 35 pg/mL by sensitive assay. Symptoms of excess (above 40 to 50 pg/mL) include nipple tenderness, bloating, emotional lability, and erectile difficulty. Symptoms of deficiency (below 15 pg/mL, often caused by overzealous aromatase inhibitor use) include joint pain, low libido, fatigue, and accelerated bone loss.

Managing Elevated Estradiol

First-line management is dose adjustment or injection frequency change (more frequent, smaller doses reduce testosterone peaks and therefore aromatization). Body fat reduction through caloric deficit and resistance training lowers aromatase activity. Anastrozole (0.25 to 0.5 mg twice weekly) is a second-line option when these measures are insufficient, per the Endocrine Society's recommendation to use the lowest effective dose [5].

The TRAVERSE Trial: What It Settled About Prostate Safety

The TRAVERSE trial, published in the New England Journal of Medicine in 2023, was specifically designed by the FDA to evaluate cardiovascular safety of TRT. It also collected prostate-cancer outcomes as a secondary endpoint.

Study Design

TRAVERSE enrolled 5,204 men aged 45 to 80 with hypogonadism (two morning total T values below 300 ng/dL) and pre-existing or high risk for cardiovascular disease. Men were randomized to 1.62% testosterone gel or placebo gel and followed for a mean of 33 months [9].

Prostate Outcomes

High-grade prostate cancer (Gleason 4+3 or higher) occurred in 0.19% of the testosterone group versus 0.12% of the placebo group, a difference that was not statistically significant (HR 1.07; 95% CI 0.31 to 3.71) [9]. PSA rose by a mean of 0.20 ng/mL in the testosterone arm versus 0.08 ng/mL in placebo at 12 months. This result confirmed that TRT does not meaningfully increase the risk of aggressive prostate cancer over a 3-year horizon. The AUA cited TRAVERSE in its 2024 updated position statement affirming that TRT is not contraindicated solely on the basis of prostate cancer concern in men without active disease [4].

Limitations

TRAVERSE excluded men with a history of prostate cancer, PSA above 4.0 ng/mL, or abnormal DRE at screening. Its findings do not extend to prostate cancer survivors. Men with treated, localized prostate cancer and undetectable PSA post-treatment may still be candidates for TRT under urological co-management, but that population requires individualized risk-benefit discussion.

Putting It Together: A Practical Monitoring Protocol

The following schedule synthesizes Endocrine Society, AUA, and American Association of Clinical Endocrinology (AACE) guidelines into a single workflow.

Before First Injection

Order: total testosterone (LC-MS/MS, two morning draws), free testosterone (calculated from SHBG), PSA, CBC with differential, CMP, lipid panel, estradiol sensitive, prolactin (if total T is below 150 ng/dL to rule out prolactinoma). Perform DRE in men over 40.

3-Month Follow-Up

Order: total testosterone (trough), free testosterone, PSA, CBC, estradiol sensitive. Assess symptom response. Adjust dose if trough T is below 450 or above 900 ng/dL, hematocrit exceeds 52%, or estradiol exceeds 40 pg/mL.

6-Month and 12-Month Follow-Up

Repeat the 3-month panel. Add lipid panel at 12 months. Confirm PSA velocity. By 12 months, PSA should have stabilized. If it has not, urology referral is indicated.

Annual Maintenance

PSA, CBC, total T (trough), estradiol sensitive, CMP, lipid panel. DRE per shared decision-making. DEXA scan at baseline and every 2 years for men over 50 or those with osteoporosis risk factors. According to the 2018 Endocrine Society guideline: "Monitor hematocrit at 3 to 6 months after treatment initiation and then annually. If hematocrit is >54%, stop therapy until hematocrit decreases to a safe level" [5].